Stéphane Bigler | EPFL Graph Search

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

A new self-adjustable glaucoma valve

Nikolaos Stergiopulos, Stéphane Bigler, Julien Maxime Gerber, Soroush Rafiei

Introduction: Glaucoma, the leading cause of irreversible blindness globally, affects more than 70 million people across the world. When initial treatments prove ineffective, especially for cases with high intraocular pressure (IOP), the preferred approach involves employing glaucoma drainage devices (GDDs). Methods: This study introduces a novel self-adjustable glaucoma drainage device (SAGDD) designed to maintain IOP within the desired biological range (10 mmHg < IOP

Frontiers Media Sa2024

Comparison Between the eyeWatch Device and the Ahmed Valve in Refractory Glaucoma

Nikolaos Stergiopulos, André Mermoud, Sylvain Roy, Adan Villamarin, Stéphane Bigler, Constantinos Stergiopulos

Purpose: To assess the efficacy and safety of a glaucoma procedure to control intraocular pressure (IOP) using the adjustable eyeWatch glaucoma drainage device compared with Ahmed glaucoma valve (AGV) in refractory glaucoma. Patients and Methods: Monocentric, retrospective, comparative clinical trial. Patients suffering from refractory glaucoma after failed surgeries and requiring a further glaucoma procedure including an aqueous shunt were enrolled in this study. The first group AGV included patients with an AGV. The second group eW-B included patients receiving an eyeWatch used in connection with a Baerveldt glaucoma implant. The primary outcome was the success rate, defined as an IOP 20% from baseline, and IOP >= 5 mm Hg. Secondary outcomes were mean IOP, number of antiglaucoma medications, visual acuity, number and type of complications. Results: Twenty-one patients were included. The mean follow-up time was 13.2 +/- 3.4 months. Mean IOP decreased from 24.8 +/- 9.0 mm Hg before surgery to 13.8 +/- 3.6 mm Hg at 12 months for group AGV, and 27.3 +/- 7.0 to 12.8 +/- 2.4 mm Hg for group eW-B, respectively (P

LIPPINCOTT WILLIAMS & WILKINS2020

Initial Clinical Results of the eyeWatch: a New Adjustable Glaucoma Drainage Device Used in Refractory Glaucoma Surgery

Nikolaos Stergiopulos, André Mermoud, Sylvain Roy, Adan Villamarin, Stéphane Bigler, Constantinos Stergiopulos

Precis: In this study, we report clinical results after implantation of an adjustable glaucoma drainage device. The intraocular pressure (IOP) profile was efficiently controlled postoperatively as the resistance to aqueous humor outflow was finely adjusted. Purpose: The main purpose of this study was to evaluate the safety and efficacy of the new adjustable glaucoma drainage device eyeWatch used in conjunction with a Baerveldt glaucoma implant in refractory glaucoma. Patients and Methods: This was a multicentric, prospective, noncomparative clinical trial. Patients older than 18 years of age suffering from refractory glaucoma after failed surgeries, with IOP of >= 20 mm Hg, in whom a further glaucoma procedure using an aqueous shunt was planned, were enrolled in this study. The primary outcome was the success rate, defined as an IOP 20% from baseline, IOP >= 6 mm Hg. Secondary outcomes were mean IOP, visual acuity, number of antiglaucoma medications, number, and type of complications. Results: Fifteen patients were included. The mean follow-up time was 15.6 +/- 3.5 months. The mean baseline IOP decreased from 26.2 +/- 6.8 mm Hg before surgery to 11.9 +/- 2.8 mm Hg at 12 months (P

LIPPINCOTT WILLIAMS & WILKINS2019